OCM
NBIX icon

Orion Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Orion Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$22.5K – 529
2023
Q3 		$22.5K Buy
+200
New +$21.1K 0.01% 312
2023
Q2 		– Sell
-200
Closed -$20.2K – 331
2023
Q1 		$20.2K Sell
200
-100
-33% -$10.4K 0.01% 315
2022
Q4 		$35.8K Hold
300
– – 0.03% 225
2022
Q3 		$32K Sell
300
-100
-25% -$10.1K 0.03% 236
2022
Q2 		$39K Hold
400
– – 0.03% 216
2022
Q1 		$38K Hold
400
– – 0.02% 227
2021
Q4 		$34K Buy
+400
New +$36.8K 0.02% 222

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Orion Capital Management's NBIX Position: Q4 2023 in Review

Orion Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 200 shares — an estimated $22.5K sold.

Orion Capital Management first reported a position in NBIX in Q4 2021 and held it in 7 quarters. The position peaked at $39K in Q2 2022. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Orion Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
  • Orion Capital Management sold 200 Neurocrine Biosciences shares in Q4 2023, an estimated $22.5K.
  • Orion Capital Management first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 7 quarters.
  • Orion Capital Management's Neurocrine Biosciences position peaked at $39K in Q2 2022.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Orion Capital Management's 13F filing for Q4 2023, filed 6 Feb 2024.